Prager, Rudolf

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 850

Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.

Bergman, R. N., Prager, R., Volund, A., & Olefsky, J. M. (1987) · Journal of Clinical Investigation

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 772

The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus

Cauza, E., Hanusch-Enserer, U., Strasser, B., Ludvik, B., Metz-Schimmerl, S., Pacini, G., Wagner, O., Georg, P., Prager, R., Kostner, K., et al. (2005) · Archives of Physical Medicine and Rehabilitation

Cardiovascular and exercise physiologyPhysical Activity and Health

Cited by 392

PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease)

Huelsmann, M., Neuhold, S., Resl, M., Strunk, G., Brath, H., Francesconi, C., Adlbrecht, C., Prager, R., Luger, A., Pacher, R., et al. (2013) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 385

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Pieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 287

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 243

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 209

Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans

Hartter, E., Svoboda, T., Ludvik, B., Schuller, M., Lell, B., Kuenburg, E., Brunnbauer, M., Woloszczuk, W., & Prager, R. (1991) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 191

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial

von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology

Diabetes and associated disordersPancreatic function and diabetes

Cited by 186

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Decrease of Stimulated Amylin Release Precedes Impairment of Insulin Secretion in Type II Diabetes

Ludvik, B., Lell, B., Hartter, E., Schnack, C., & Prager, R. (1991) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 82

β-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects

Kautzky-Willer, A., Thomaseth, K., Clodi, M., Ludvik, B., Waldhäusl, W., Prager, R., & Pacini, G. (1996) · Metabolism

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35